FOLH1 and metastatic neoplasm: In patients with PSA level < 5 ng/mL, 17.6% of patients had PSMA-positive bone lesions with similar numbers in all three patient groups; this indicates a potential benefit of PSMA PET/CT in patients with lower PSA levels, in whom the metastatic disease may otherwise be missed.